For Healthcare Professionals

This page is for healthcare professionals. It collects short summaries of recent studies and developments in radiation oncology, with a link to the original paper for each one. It is updated as notable studies are published. For patient information, please see the other pages on this site.

About these updates

Each update gives the study name or topic, where it was published, the key numbers, and a short note on what it may mean for practice — including what the study does not prove. Summaries are brief and are not a substitute for reading the full paper or for clinical judgement.

Endometrial cancer: molecular types and radiotherapy

Topic summary · ESGO–ESTRO–ESP 2025 · PORTEC-3 · PORTEC-4a · RAINBO

How the four molecular types (POLEmut, MMRd, NSMP, p53abn) change the risk group and the adjuvant radiotherapy decision — who can omit treatment, who needs brachytherapy or pelvic EBRT, and who needs chemoradiation.

Read the full summary

MASTERPLAN trial: SBRT in pancreatic cancer

Lancet Oncology · Oct 2026 · Randomised phase II · ESMO 2026

Adding SBRT (40 Gy in 5 fractions) to chemotherapy halved 12-month locoregional recurrence — 20.2% vs 52.0% — in high-risk localised pancreatic cancer, with a survival signal that needs phase III confirmation.

Read the full summary

HARVEST trial

Int J Radiat Oncol Biol Phys · Nov 2026 · Phase III

Hypofractionated vs conventional breast radiotherapy, both with comprehensive regional nodal irradiation including the internal mammary nodes.

801
patients, 8 centres in China
15 vs 25
fractions — 40.05 Gy vs 50 Gy
RR 0.48
grade ≥2 skin dermatitis with hypofractionation (lower)
>90%
protocol compliance
Bottom line: Acute toxicity overall was not significantly different between the two schedules, and cosmesis was comparable.

What it doesn’t prove: Early toxicity data only — long-term cancer control and late effects, including cardiac effects, are still awaited.

Full paper: DOI 10.1016/j.ijrobp.2026.10.050

IDEA trial, long-term follow-up

JAMA Oncology · Nov 2026 · Single-arm prospective study

Endocrine therapy alone, no radiotherapy after breast-conserving surgery, in postmenopausal patients aged 50–69 with stage I ER-positive, HER2-negative cancer and Oncotype RS ≤18.

200
patients
7.93 yrs
median follow-up
99%
freedom from recurrence at 5 years
94%
freedom from recurrence at 8 years
Bottom line: Most ipsilateral events occurred after 5 years, so long follow-up matters in this low-risk group.

What it doesn’t prove: Single-arm study with no radiotherapy comparison group — results depend on patients continuing endocrine therapy.

Full paper: DOI 10.1001/jamaoncol.2026.4529

SRAM trial, 12-month update

Radiotherapy and Oncology · Nov 2026 · Randomised phase II

Pelvis-inclusive SBRT (40 Gy prostate / 25 Gy pelvis in 5 once-weekly fractions) vs IMRT (76 Gy in 38 fractions) in high-risk prostate cancer.

121
men randomised
16.7% vs 13.1%
grade ≥2 GI toxicity, 6–12 months (SBRT vs IMRT)
11.7% vs 16.4%
grade ≥2 GU toxicity, 6–12 months
1
grade 3 rectal haemorrhage (after SBRT)
Bottom line: No significant difference in grade ≥2 GI or GU toxicity, but patient-reported bowel scores were worse with SBRT at 9 and 12 months.

What it doesn’t prove: Phase II, 121 patients — cancer-control outcomes are not yet reported.

Full paper: DOI 10.1016/j.radonc.2026.111870

Staying up to date

Short summaries of selected studies are also shared on LinkedIn as they are published. Healthcare professionals are welcome to get in touch via the Contact page about referrals, second opinions, or collaboration.

This page is for healthcare professionals and is general information only. It does not replace the full text of the cited studies, clinical guidelines, or individual clinical judgement.